SCHEMBL30596373

SCHEMBL30596373

COC(=O)Nc1nc2cc(Sc3ccc(-c4cc(C)cs4)cc3)ccc2[nH]1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 8/20 0.57
CYP1A2 P05177 6/20 0.57
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
NR1I2 O75469 1/20 0.57
MAPK14 Q16539 1/20 0.57
HIF1A Q16665 5/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
CYP2C19 P33261 1/20 0.47
MAPK1 P28482 4/20 0.46
TP53 P04637 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
HPGD P15428 2/20 0.46
KCNH2 Q12809 1/20 0.46
KDR P35968 3/20 0.45
TEK Q02763 1/20 0.45
MMP1 P03956 1/20 0.45
TUBB4A P04350 4/20 0.43
TUBB P07437 4/20 0.43
TUBA3C P0DPH7 4/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26433353 1.00 LMNA (0.57) LMNACYP1A2MEN1KMT2ANR1I2
SCHEMBL26110486 0.91 LMNA (0.47) LMNACYP1A2MEN1KMT2ANR1I2
SCHEMBL26433080 0.87 LMNA (0.58) LMNACYP1A2MEN1KMT2ANR1I2
SCHEMBL30596372 0.87 LMNA (0.58) LMNACYP1A2MEN1KMT2ANR1I2
SCHEMBL24359560 0.86 LMNA (0.60) LMNACYP1A2MEN1KMT2ANR1I2
SCHEMBL29599971 0.86 LMNA (0.60) LMNACYP1A2MEN1KMT2ANR1I2
Fenbendazole SCHEMBL31547327 0.82 LMNA (0.82) LMNACYP1A2MEN1KMT2ANR1I2
Fenbendazole SCHEMBL31547342 0.82 LMNA (0.82) LMNACYP1A2MEN1KMT2ANR1I2
Fenbendazole SCHEMBL166352 0.82 LMNA (0.82) LMNACYP1A2MEN1KMT2ANR1I2
Fenbendazole SCHEMBL3988034 0.82 LMNA (0.82) LMNACYP1A2MEN1KMT2ANR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214945-A1 THIOBENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) 2025-07-03 US disclosed
EP-4506346-A1 THIOBENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF Korea University Research and Business Foundation (KR) 2025-02-12 EP disclosed
WO-2023191536-A1 THIOBENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF 고려대학교 산학협력단 2023-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214945-A1 THIOBENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF TTBK2, TUBB3, TUBB LMNA 4174/4885CYP1A2 2984/4885MEN1 4333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.